Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | Opicapone in PD with motor fluctuations: post-hoc analysis of BIPARK-I and II

Georg Ebersbach • 27 May 2020
EAN 2020
Movement Disorders Parkinson's Disease Levodopa Opicapone
BIPARK-I BIPARK-II

Georg Ebersbach, MD, Movement Disorders Clinic, Beelitz‐Heilstätten, Germany, discusses the efficacy and safety of opicapone in Parkinson’s disease patients according to the duration of motor fluctuations. In particular, Dr Ebersbach outlines the post-hoc analysis of the BIPARK-I and BIPARK-II trials. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Georg Ebersbach

2:40
Future treatment directions for Parkinson's disease
Georg Ebersbach • 27 May 2020
2:07
Parkinson's disease: physiotherapy, speech and occupational therapy
Georg Ebersbach • 27 May 2020
3:59
OPTIPARK trial: opicapone in clinical practice
Georg Ebersbach • 27 May 2020

Related Videos

5:26
Pridopidine shows benefit for patients with early HD not on antidopaminergic therapies
Michael Hayden • 16 Apr 2024
2:51
Overlap in etiology between different FND subtypes
Mark Hallett • 15 Apr 2024
1:58
Ambroxol & other targeted therapies in Parkinson's
K Ray Chaudhuri • 21 Mar 2024
3:00
The use of precision medicine in Parkinson’s disease
K Ray Chaudhuri • 21 Mar 2024
The content of VJNeurology is intended for healthcare professionals